Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

Sponsor
UNC Lineberger Comprehensive Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05754749
Collaborator
(none)
20
1
1
19.1
1

Study Details

Study Description

Brief Summary

The purpose of this pilot study is to compare radiologist confidence level in evaluating patients with known breast lesions between contrast enhanced digital breast tomosynthesis (CE- DBT) and contrast enhanced dynamic magnetic resonance imaging (CE-MRI) acquired as a part of a standard clinical workup.

Condition or Disease Intervention/Treatment Phase
  • Drug: Iohexol 350 Mg/mL Injectable Solution
Early Phase 1

Detailed Description

This is a pilot study of CE-DBT scans to evaluate its utility relative to breast CE-MRI. Twenty women who have planned or received conventional breast MRI imaging at UNC Hospitals will be recruited for the study. Participants will be scanned with the DBT system after the administration of iodinated contrast agent. We will acquire images prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Comparison of Contrast Enhanced Digital Breast Tomosynthesis and Magnetic Resonance Imaging in Patients With Known Breast Lesions
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Contrast-enhanced digital breast tomosynthesis (CE-DBT)

Participants with known breast lesions will be imaged using contrast-enhanced digital breast tomosynthesis (CE-DBT) with Iohexol 350 mg I/mL.

Drug: Iohexol 350 Mg/mL Injectable Solution
Participants will be scanned with the digital breast tomosynthesis (DBT) system before and after the intravenous administration of iodinated contrast agent, iohexol 350mg I/mL at a dose of 1.5 mL/kg body weight. We will acquire images of the breast of interest prior to the administration of contrast, followed by at approximately 2 minutes and 5 minutes after administration. For the purposes of this study, imaging will focus on a single breast to simplify data acquisition.
Other Names:
  • Contrast- enhanced digital breast tomosynthesis (CE-DBT)
  • Outcome Measures

    Primary Outcome Measures

    1. Reader confidence in identifying lesions on CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the reader confidence in identifying lesions on CE-DBT to the reader confidence in identifying lesions on contrast enhanced dynamic breast MRI.

    Secondary Outcome Measures

    1. Contrast enhancement curves of CE-DBT compared to conventional MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the contrast enhancement curves of CE-DBT to the contrast enhancement curves of contrast enhanced dynamic breast MRI in evaluation of known breast lesions for predicting malignancy.

    2. Diagnostic accuracy of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the diagnostic accuracy of CE-DBT to the diagnostic accuracy of contrast enhanced dynamic breast MRI in evaluation of known breast lesions for predicting malignancy.

    3. Sensitivity of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the sensitivity of CE-DBT to the sensitivity of contrast enhanced dynamic breast MRI in evaluation of known breast lesions for predicting malignancy.

    4. Specificity of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the specificity of CE-DBT to the specificity of contrast enhanced dynamic breast MRI in evaluation of known breast lesions for predicting malignancy.

    5. Positivity predictive value of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the positivity predictive value of CE-DBT to the positivity predictive value of contrast enhanced dynamic breast MRI in evaluation of known breast lesions for predicting malignancy.

    6. Receiver Operating Characteristic (ROC) curves of CE-DBT compared to contrast enhanced dynamic breast MRI (arbitrary units) [Calculated once all imaging is complete [Anticipated 1.5 years]]

      To compare (using a reader study) the ROC curves of CE-DBT to the ROC curves of contrast enhanced dynamic breast MRI in evaluation of known breast lesions for predicting malignancy.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women at least 18 years old

    • Planned or received conventional breast MRI at UNC Hospitals within 3 months prior to or after the research scan

    • Suspected breast lesion based on prior imaging (BIRADS 4 or greater)

    • Able to provide written informed consent

    Exclusion Criteria:
    • Severe untreatable claustrophobia

    • Implanted metallic devices, parts, vascular clips, or other foreign bodies (including breast implants)

    • Known hypersensitivity to iodinated contrast agent or to any component of iodinated contrast refractory to standard medications (antihistamines, steroids)

    • Impaired kidney function (serum creatinine level > 1.8 mg/dl or a glomerular filtration rate < 60 as approximated using serum creatinine levels) unless anuric and on dialysis

    • Any woman who is pregnant or has reason to believe she is pregnant (the possibility of pregnancy has to be excluded by negative urine β-HCG results, obtained within 24 hours prior to the research scan, or on the basis of patient history, as defined by the UNC IRB SOP 4801)

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of North Carolina at Chapel Hill Chapel Hill North Carolina United States 27599

    Sponsors and Collaborators

    • UNC Lineberger Comprehensive Cancer Center

    Investigators

    • Principal Investigator: Rachel Hitt, MD, University of North Carolina, Chapel Hill

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    UNC Lineberger Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT05754749
    Other Study ID Numbers:
    • LCCC2139
    First Posted:
    Mar 6, 2023
    Last Update Posted:
    Mar 6, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No

    Study Results

    No Results Posted as of Mar 6, 2023